Изработка на уеб сайт от Web IT Solutions

EMV Capital closes £2.9m pre-series A round for SageTech Medical

  • Technology allows hospitals to expand operating theatre/ICU capacity quickly
  • Helps to solve problem of waste anaesthetic gas – a major source of greenhouse gases


13th May 2021, London (PRWEB)

Anaesthetic gas recycling technology firm SageTech Medical Equipment Ltd (SageTech) has completed a £2.9m pre-series A investment, including £1.6m investment introduced by specialist venture capitalist EMV Capital.

As part of restructuring the company’s arrangements for the commercialisation of the business, EMV Capital’s parent company NetScientific PLC purchased £200k of shares, in line with its direct investment strategy and demonstrating the Group’s commitment to SageTech.

SageTech’s flexible, low-capex, modular system allows hospitals to capture waste anaesthetic gas exhaled by patients in absorbent, reusable canisters in the operating theatre. These canisters are emptied, the gas stored in bulk tanks and then collected by SageTech. The firm is currently developing technology which will allow this gas to be recycled, purified and sold commercially.

Waste anaesthetic gases are a substantial and broadly unaddressed cause of air pollution. Currently anaesthetic gas used by hospitals is captured by centralised hospital systems, and vented out into the atmosphere. The anaesthetic gas used by a midsized hospital has the same environmental impact as 1,200 cars each year. The NHS produces 5.4% of all the greenhouse gases in the UK, as more than 95% of all the anaesthetic gas used is disposed of into the atmosphere.

SageTech’s technology allows hospitals to use anaesthetic gas in areas that do not have access to fixed Anaesthetic Gas Scavenging Systems, the current solution used by hospitals to collect these gases. These systems are built into a hospital’s infrastructure when it is constructed, meaning that hospitals have not been able to expand operating theatre and intensive care capacity easily during the Covid-19 pandemic. SageTech systems can allow for ‘temporary’ operating theatres to be used.

This pre-series A round is part of a fundraising strategy to complete pilots that are currently underway within UK hospitals and to scale up commercial operations to meet demonstrated global demand for their technology platform. The funding will also be used to further development towards market authorisation for SageTech’s recycled anaesthetic product.

This investment follows a successful first close alongside existing investors in November 2020. Since the first close of this investment round, John Clarkson (Chairman of NetScientific PLC, EMV Capital’s parent company) has joined the board of SageTech, bringing his wealth of commercial expertise to the next stage of the company’s growth.

John Clarkson comments, “The last year has proven the need for SageTech’s technology. As the UK and many other countries focus on achieving net zero by 2050, the case for anaesthetic gas recycling is only going to get stronger.”

“For 95% of all anaesthetic gas to be wasted is something that simply must change. SageTech is well-positioned to be at the forefront of that change.”

“This funding round is going to power SageTech’s scaleup and it’s hugely exciting for NetScientific PLC and EMV Capital to be part of that. “

Commenting on this investment round, Iain Menneer, SageTech CEO “The successful close of the pre-Series A round is further endorsement of SageTech Medical’s innovative technology and business proposition. Recent fundraising gives the company the resources to complete development and final clinical testing with UK hospitals before launching our anaesthetic waste capture solution later this year.”

“We have also attracted talented and committed individuals to complement the SageTech team. Demand from hospitals has remained high despite the inevitable demands of the pandemic. So in short, we now have the necessary ingredients to embark upon the next exciting chapter of SageTech’s story.”


About SageTech Medical Equipment Ltd


SageTech Medical Equipment Ltd specialises in the development and commercialisation of patented technology. Its technology is applicable to several industries but is being applied initially in healthcare as an exemplar to reduce the environmental and financial costs associated with anaesthesia. The technology is internationally scalable and provides significant flexibility and scalable advantages to healthcare. SageTech’s solution offers large financial savings on hospital infrastructure installations and maintenance costs in time eliminating the need for expensive air extraction systems to take the exhaled drugs from the operating theatres to the chimney.

SageTech Medical has attracted interest and enquiries from clinicians in the UK, Europe, America, Australia and Scandinavia, all driven to reduce environmental damage, increase efficiency and reduce costs.

About EMV Capital Ltd


EMV Capital Ltd (EMVC), a wholly-owned subsidiary of NetScientific PLC, is a London-based investment services company focused on B2B companies in industrial high-tech, energy and healthcare. EMVC’s multidisciplinary team has expertise in venture investment, corporate development, corporate finance and M&A. EMVC understands the importance and value of environmental sustainability and ethical investment principles, reflecting this within its investment thesis.

EMV Capital has a growing EIS investment practice, and is an exclusive advisor to the EMVC Evergreen EIS Fund (http://emvcapital.com/eis_fund/)

EMV Capital Limited is an appointed representative of Sapphire Capital Limited, which is authorised and regulated by the Financial Conduct Authority.

About NetScientific PLC AIM-listed NetScientific Plc is a life sciences and sustainability technology investment and commercialisation Group, leveraging trans-Atlantic relationships and global opportunities to deliver shareholder value. For more information, please visit the website at www.NetScientific.net

Leave a comment


Investing in start-ups and early-stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution. It should be done only as part of a diversified portfolio. Any investments are targeted exclusively at investors who understand the risks of investing in early-stage businesses and can make their own investment decisions. Any pitches for investment are not offers to the public. Investments made in investee companies via funds managed by Sapphire Capital Partners LLP are not covered by the Financial Services Compensation Scheme (FSCS). For more details, please contact us or refer to their website: https://www.fscs.org.uk


Don’t invest unless you’re prepared to lose all the money you invest. This is a high risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more.